Rico-Villademoros, Fernando, Rodriguez-Lopez, Carmen Maria, Morillas-Arques, Piedad et al. · Clinical rheumatology · 2012 · DOI
Researchers tested whether a medication called amisulpride, which is sometimes used to treat pain and mood problems, could help people with fibromyalgia. Over 12 weeks, 40 patients took this medication along with their regular treatments. The medication did not significantly reduce pain or other fibromyalgia symptoms, and many patients stopped taking it because of side effects.
Although this study focused on fibromyalgia rather than ME/CFS, it is relevant because the authors note amisulpride had shown promise in chronic fatigue syndrome. Understanding why a medication failed in fibromyalgia—despite theoretical benefit in related conditions—provides important information about treatment selection and the differences between overlapping pain and fatigue disorders.
This uncontrolled, open-label design cannot establish that amisulpride is ineffective in fibromyalgia or ME/CFS, only that it showed no benefit in this small, poorly-tolerated trial. The lack of a control group means placebo effects and natural variation cannot be separated from drug effects. High dropout rates (65%) bias results toward remaining patients and may not represent the full patient population.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.